29
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          In healthy carriers of the T allele of the transcription factor 7-like 2 ( TCF7L2), fasting plasma glucagon concentrations are lower compared with those with the C allele. We hypothesised that presence of the T allele is associated with a diminished glucagon response during hypoglycaemia and a higher frequency of severe hypoglycaemia (SH) in type 1 diabetes (T1DM).

          Material and methods

          This is a post hoc study of an earlier prospective observational study of SH and four mechanistic studies of physiological responses to hypoglycaemia. 269 patients with T1DM were followed in a one-year observational study. A log-linear negative binomial model was applied with events of SH as dependent variable and TCF7L2 alleles as explanatory variable. In four experimental studies including 65 people, TCF7L2 genotyping was done and plasma glucagon concentration during experimental hypoglycaemia was determined.

          Results

          Incidences of SH were TT 0.54, TC 0.98 and CC 1.01 episodes per patient-year with no significant difference between groups. During experimental hypoglycaemia, the TCF7L2 polymorphism did not influence glucagon secretion.

          Discussion

          Patients with T1DM carrying the T allele of the TCF7L2 polymorphism do not exhibit diminished glucagon response during hypoglycaemia and are not at increased risk of severe hypoglycaemia compared with carriers of the C allele.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: not found
          • Article: not found

          Diabetes

            • Record: found
            • Abstract: found
            • Article: not found

            Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia.

            To determine the frequency of hypoglycemia in patients with type I diabetes and impaired awareness of hypoglycemia by prospective assessment. A prospective study was undertaken for 12 months in 60 patients with type I diabetes: 29 had impaired awareness of hypoglycemia and 31 retained normal awareness of hypoglycemia. The two groups of patients were matched for age, age at onset of diabetes, duration of diabetes, and glycemic control. Episodes of severe hypoglycemia were recorded within 24 h of the event and verified where possible by witnesses. During the 12 months, 19 (66%) of the patients with impaired awareness had one or more episodes of severe hypoglycemia with an overall incidence of 2.8 episodes.patient-1.year-1. By comparison, 8 (26%) of the patients with normal awareness experienced severe hypoglycemia (P < 0.01) with an annual incidence of 0.5 episode.patient-1.year-1 (P < 0.001). Severe hypoglycemia occurred at different times of the day in the two groups: patients with impaired awareness experienced a greater proportion of episodes during the evening (P = 0.03), and patients with normal awareness experienced a greater proportion in the early morning (P = 0.05). An assessment of fear of hypoglycemia revealed that patients with impaired awareness of hypoglycemia worried more about hypoglycemia than did patients with normal awareness (P = 0.008), but did not modify their behavior accordingly. This prospective evaluation demonstrated that impaired awareness of hypoglycemia predisposes to a sixfold increase in the frequency of severe hypoglycemia, much of which occurred at home during waking hours.
              • Record: found
              • Abstract: found
              • Article: not found

              Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

              Genetic variants in the gene encoding for transcription factor-7-like 2 (TCF7L2) have been associated with type 2 diabetes (T2D) and impaired beta cell function, but the mechanisms have remained unknown. We therefore studied prospectively the ability of common variants in TCF7L2 to predict future T2D and explored the mechanisms by which they would do this. Scandinavian subjects followed for up to 22 years were genotyped for 3 SNPs (rs7903146, rs12255372, and rs10885406) in TCF7L2, and a subset of them underwent extensive metabolic studies. Expression of TCF7L2 was related to genotype and metabolic parameters in human islets. The CT/TT genotypes of SNP rs7903146 strongly predicted future T2D in 2 independent cohorts (Swedish and Finnish). The risk T allele was associated with impaired insulin secretion, incretin effects, and enhanced rate of hepatic glucose production. TCF7L2 expression in human islets was increased 5-fold in T2D, particularly in carriers of the TT genotype. Overexpression of TCF7L2 in human islets reduced glucose-stimulated insulin secretion. In conclusion, the increased risk of T2D conferred by variants in TCF7L2 involves the enteroinsular axis, enhanced expression of the gene in islets, and impaired insulin secretion.

                Author and article information

                Journal
                Endocr Connect
                Endocr Connect
                EC
                Endocrine Connections
                Bioscientifica Ltd (Bristol )
                2049-3614
                November 2016
                03 November 2016
                : 5
                : 6
                : 53-60
                Affiliations
                [1 ]Department of Cardiology Nephrology and Endocrinology, Nordsjællands Hospital, Hillerød, Denmark
                [2 ]Faculty of Health and Medical Sciences University of Copenhagen, Copenhagen, Denmark
                [3 ]Lægerne på Ellemarksvej Køge, Denmark
                [4 ]Department of Cardiology Herlev-Gentofte University Hospital, Herlev, Denmark
                [5 ]Novo Nordisk A/S Søborg, Denmark
                [6 ]Steno Diabetes Center Gentofte, Denmark
                [7 ]Lund University Diabetes Centre Skåne University Hospital, Malmø, Sweden
                [8 ]Finnish Institute for Molecular Medicine (FIMM) Helsinki University, Helsinki, Finland
                [9 ]Department of Biomedical Sciences NNF Center for Basic Metabolic Research, The Panum Institute, Copenhagen, Denmark
                [10 ]Department of Endocrinology Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
                Author notes
                Correspondence should be addressed to P L Kristensen; Email: peter.lommer.kristensen.01@ 123456regionh.dk
                Article
                EC160050
                10.1530/EC-16-0050
                5097143
                27758844
                f24f161b-b6f0-4dcb-80cf-5fcb44d0b1e1
                © 2016 The authors

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 6 September 2016
                : 10 October 2016
                Categories
                Research

                type 1 diabetes,severe hypoglycaemia,tcf7l2,glucagon,epidemiology,experimental hypoglycaemia

                Comments

                Comment on this article

                Related Documents Log